Search results
Showing 91 to 105 of 162 results for atrial fibrillation
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (IPG598)
Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).
Discontinued [GID-TAG377]
Discontinued [GID-TAG383]
subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation, osteoporosis, dementia, and death, including...
(older children) - inhaler devices 13 February 2002 TA249 Atrial fibrillation - dabigatran etexilate 7 February 2012 TA098 Attention...
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued [GID-TAG416]
NICE guidance that could generate cost savings.
completed (16 people needed chest X-ray to confirm tip position due to atrial fibrillation or contra-indication to ECG but all were able...
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013
(non-remunerated) Chair Pfizer/Bristol Myers Squibb independent atrial fibrillation detection improvement grants – not product related....
(non-remunerated) Chair Pfizer/Bristol Myers Squibb independent atrial fibrillation detection improvement grants – not product related....
(non-remunerated) Chair Pfizer/Bristol Myers Squibb independent atrial fibrillation detection improvement grants – not product related....